Dewpoint Therapeutics
Chris Luciano is an experienced accountant currently working at Dewpoint Therapeutics since May 2021. Prior to this role, Chris held accounting positions at The Bollard Group from October 2020 to May 2021 and at Boston Capital from September 2018 to October 2020. Chris earned a Bachelor’s Degree in Accounting from Marquette University, completing the program in 2018, and graduated from Boston College High School in 2013.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.